• Specialty billing guide Dermatology

Dermatology billing: the cosmetic line, modifier 25, and the bundling edits behind your denials

Last updated: August 2026

By Mindy Corbett, CSPO, CPC, CPB, CPPM · 15 years RCM leadership · Updated August 2026 · 14 min read

THE BOTTOM LINE

Most dermatology denials are decided before the claim ever goes out. Usually before the patient leaves the room.

Three things drive the pattern: whether the diagnosis on the claim supports coverage, whether the E/M note stands on its own apart from the procedure note, and whether the procedure codes you billed together are allowed to be billed together. Get those three right at the point of documentation and the back end mostly takes care of itself.

This guide walks the visit in the order it actually happens, from the front desk to the remittance advice.

Definitions and frequently used terms

I define these up front for two reasons. Some readers genuinely have not seen them before, and there is no shame in that. The rest of us use them slightly differently depending on where we trained, and it helps to agree on what we mean before we start.

CARC. Claim Adjustment Reason Code. The numeric code on your remittance advice that tells you why an amount was adjusted. Maintained by X12, not by your payer, which matters when you appeal.

RARC. Remittance Advice Remark Code. The M, N, and MA prefixed codes that add detail to a CARC. A CARC tells you the category. A RARC usually tells you the specific reason.

NCCI. National Correct Coding Initiative. The CMS program that defines which procedure code pairs may be billed together.

PTP edit. Procedure-to-Procedure edit. One specific code pair inside NCCI, with a Column One code, a Column Two code, and a modifier indicator.

Modifier indicator. The number attached to each PTP pair that tells you whether a modifier can override the edit. Indicator 1 means a modifier can bypass it when the clinical facts support that. Indicator 0 means nothing bypasses it, and the Column Two code should not be billed.

LCD. Local Coverage Determination. A coverage policy issued by a Medicare Administrative Contractor for its own jurisdiction. IMPORTANT: an LCD is not national policy. More on this below, because it trips up more people than any other item on this list.

MAC. Medicare Administrative Contractor. The regional contractor that processes your Medicare claims and writes the LCDs you are subject to.

TC and 26. The technical component and the professional component of a service that has both. TC is the processing. 26 is the interpretation.

Start with the diagnosis, because everything else hangs on it

The cosmetic versus medically necessary question is the most financially consequential decision in dermatology, and it gets made in the exam room, not in the billing office.

Here is the part that is easy to miss. The procedure does not determine coverage. The clinical condition does. The same excision on the same patient at the same site is covered or non-covered depending entirely on what the record says about why it was done.

A lipoma that sits there quietly is cosmetic. A lipoma compressing a nerve is not. A sebaceous cyst that has never caused a problem is cosmetic. A cyst with recurrent infection, pain, and drainage is not. The paid claim and the denied claim can be clinically identical procedures. What separates them is whether someone wrote down the functional problem.

So the documentation has to name the covered condition explicitly. Inflammation. Infection. Bleeding. Functional impairment. Clinical suspicion of malignancy. Then the ICD-10-CM code on the claim has to match what was documented. If the encounter is coded Z41.1 (encounter for cosmetic surgery), no amount of clinical detail in the note will save it. The claim will deny on the diagnosis before anyone reads the procedure note.

About those coverage policies

You will see people cite LCD L39506 (Cosmetic and Reconstructive Surgery) as though it were the national Medicare rule on this. It is not.

L39506 is issued by CGS Administrators and applies in Kentucky and Ohio only. Its subject matter is breast reconstruction and reduction, rhinoplasty and septoplasty, panniculectomy, and liposuction. It does not address skin lesion destruction or removal at all. If you are outside those two states, or you are looking for lesion removal criteria, it is the wrong document.

L34938 (Removal of Benign Skin Lesions) is closer to what most dermatology practices need, and it is issued by Novitas Solutions, covering Arkansas, Colorado, Delaware, the District of Columbia, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, and Texas.

NOTE: find your own MAC’s LCD and its companion billing and coding article, and use that. Novitas publishes A57113 and A57482 alongside L34938, and the companion articles are usually where the actual code and diagnosis lists live. When you link an LCD internally, link it without the version parameter so your link always resolves to the current version. Pinned version links go stale quietly, which is the worst way for a reference to fail.

Picking the procedure code

Dermatology runs on a handful of code families. Most billing errors in this specialty are a family selected correctly and a unit or a modifier applied incorrectly.

Biopsy: 11102 through 11107

IMPORTANT: if you are still working from 11100 and 11101, those codes were deleted January 1, 2019. They come up often enough in older reference material that it is worth saying plainly. I still see them in templates.

The current structure is organized by technique, not by lesion count:

  1. 11102 tangential biopsy, first lesion, with +11103 as the add-on for each additional lesion
  2. 11104 punch biopsy, first lesion, with +11105 as the add-on for each additional lesion
  3. 11106 incisional biopsy, first lesion, with +11107 as the add-on for each additional lesion

When more than one technique is used at a single encounter, report the highest-valued primary code once and use add-ons for the remaining lesions.

Excision: benign and malignant are different ranges

Benign lesion excision by site and size is 11400 through 11446. Malignant lesion excision is 11600 through 11646. The remaining codes in the benign family, 11450 through 11471, are not lesion excisions at all, they are excisions for hidradenitis and pilonidal disease, so do not pull them in when you are sizing a lesion.

The distinction matters most in the scenario people ask about constantly, which is the biopsy that comes back positive. If you biopsied a lesion at one encounter and excised it at a later encounter based on the pathology, both services are billable. But the excision in that sequence is usually a malignant excision, so it codes to 11600-11646. Reaching for the benign range out of habit is a quiet undercode.

Shave removal: 11300 through 11313

Coded by site and lesion diameter.

Destruction: know which family you are in

This is where I see the most confusion, so let me lay the families out separately.

IMPORTANT: 17003 is a per-lesion code, not a range. The descriptor reads “second through 14 lesions, each.” If you destroy 10 premalignant lesions in a session, you report 17000 once and 17003 nine times. Reporting 17003 as a single unit for the whole session is a straightforward undercode, and it is common. CMS caps 17003 at 13 units per date of service, and when 15 or more lesions are treated, 17004 replaces 17000 and 17003 entirely rather than adding to them.

Every one of these families requires a diagnosis that matches the family. L57.0 is actinic keratosis. A benign lesion code supports 17110-17111. A malignant diagnosis supports 17260-17286. Submitting a destruction code with a cosmetic encounter diagnosis, or with a diagnosis that belongs to a different family, denies as CARC 50 or CARC 167.

Mohs: 17311 through 17315

Mohs has a documentation standard unlike anything else in the specialty, because CPT requires a single physician to act in two separate capacities, surgeon and pathologist, on the same tissue. If the surgeon does not personally perform the histologic interpretation, this is not Mohs and you code the standard excision instead.

Each stage needs a tissue map or diagram, the dimensions of the excision, the pathologic interpretation of that stage’s margins, and the decision to proceed or close. The frozen section interpretation has to be contemporaneous. Reconstructing it days later from a shorthand note will not hold up.

IMPORTANT, and this one has compliance teeth: do not bill surgical pathology codes 88302-88309 or 88331-88332 on Mohs margin tissue. Per CMS billing and coding article A56515, doing so “will indicate that true Mohs surgery was not done.” The pathology interpretation is already inside the Mohs code. If you also bill it separately, you have told the payer in writing that the service you billed was not the service you performed.

I am flagging this because the TC/26 guidance further down is correct for routine in-office pathology and wrong for Mohs, and it is an easy trap to walk into if you read the two sections independently.

The E/M question: modifier 25

Modifier 25 draws sustained scrutiny in dermatology, and the reason is structural rather than suspicious. This specialty performs an unusually high volume of same-day procedures, so a large share of its claims present the exact fact pattern payers audit.

The test is whether the evaluation and management service was significant and separately identifiable from the work that is already built into the procedure. Every procedure includes some assessment. That built-in assessment is not a billable E/M.

A patient comes in for a mole removal, the note documents the mole, the mole comes off. One service. No modifier 25.

A patient comes in with a rash on the back and a suspicious lesion on the forearm, gets a full skin exam, has medical decision-making documented about the rash, and then has the forearm lesion removed. Two services, and the record shows it.

What makes the difference is not the modifier. It is whether the E/M documentation stands up if you cover the procedure note with your hand. That means a distinct chief complaint, history addressing something beyond the procedure site, exam findings that inform decision-making independent of the procedure, and a plan that addresses both.

A post-procedure template note repurposed as an E/M note does not survive review, and it should not. If you would not be able to defend it reading it cold, neither will the payer’s reviewer.

When you bill more than one procedure: NCCI

NCCI defines which code pairs can go on the same claim. The PTP edit files update quarterly. The version effective January 1, 2026 is Version 32.0, and each quarterly release is worth running against your own top code pairs rather than reading in full.

Before you reach for a modifier, check the modifier indicator on the specific pair.

Modifier 59 and the X modifiers

Modifier 59 means distinct procedural service. The X modifiers are more specific subsets:

CMS’s stated position in NCCI Policy Manual Chapter 1 is that modifier 59 “shall only be used if no other modifier more appropriately describes the relationships,” and that the X modifiers may be used in lieu of 59 whenever possible. In dermatology the one you will reach for most is XS, for procedures on genuinely distinct anatomic sites.

Note that CMS says “whenever possible,” not “required,” and a number of commercial payers still prefer 59. This is a place to check payer policy rather than standardize on one answer.

My own view, and I will label it as mine rather than dress it up as policy: I would rather see XS on a claim where XS is true. A specific modifier tells the reviewer what actually happened. A generic one asks them to take your word for it.

The biopsy and excision pair

This is the most common bundling question in dermatology, and the usual explanation of it is slightly wrong in a way that costs practices money.

NCCI Policy Manual Chapter 3 says lesion removal codes include procurement of tissue from the same lesion by biopsy at the same encounter, and that 11102-11107 are not separately reportable in that situation. Same lesion, same day, biopsy folds into the removal.

But the manual also says biopsy codes “may be separately reportable with lesion removal codes if the biopsy is performed on a different lesion than the removal procedure.” These pairs generally carry modifier indicator 1.

So the barrier is clinical, not mechanical. Different lesion or different encounter, and you have a legitimately separate service. Same lesion, same encounter, and no modifier makes it separate. A modifier appended to a same-lesion biopsy is a bypass without clinical support, and that is exactly what post-payment review looks for.

Mutually exclusive pairs

Some code combinations describe things that cannot both have happened. A lesion that was excised was not also destroyed. A lesion that was destroyed left no specimen to excise. Billing a shave removal and an excision at the same site has the same problem.

Screen these for clinical plausibility before submission, because there is no documentation that makes an impossible pair possible.

One correction to a claim I have seen repeated: mutually exclusive denials are not automatically un-bypassable. CMS folded the separate mutually exclusive edit table into the PTP table back in 2011, so these pairs carry ordinary modifier indicators now. Check the indicator like you would for any other pair.

In-office pathology: TC and 26

If your practice processes specimens in-office, the split is straightforward once you know who did what:

  1. The entity that processes the specimen bills the pathology code with modifier TC
  2. The pathologist who interprets the slides bills the same code with modifier 26
  3. An entity performing both components bills the global code with no modifier

The failure mode is billing the global code and then also billing TC or 26 for the same date and service, which creates two payment attempts for the same work and denies as CARC 18.

The arrangement that catches practices most often is the mixed one: an outside reference lab does the processing while an in-house pathologist reads the slides. In that setup you bill 26 only, and it is worth confirming the reference lab is billing its TC separately rather than billing global.

SAVE this as a recurring task: pull the last 90 days of pathology claims once a quarter and confirm the component modifiers are right, the reference lab is not duplicating your component, and no global code went out for work that was split. TC/26 errors compound quietly across a billing period, and they are much easier to catch at 90 days than at 90 claims.

And as noted above, none of this applies to Mohs margin tissue.

Reading the remittance: what these CARCs actually mean

I am going to quote these from the X12 definitions rather than paraphrase them, because paraphrased CARC definitions have a way of drifting until they describe a different code. If you are writing an appeal, the payer is reading the official text.

CARC 4 | “The procedure code is inconsistent with the modifier used.” Where you see it: modifier 25 denials, and modifier problems generally. The E/M documentation did not stand apart from the procedural work. You will see this code rendered elsewhere with a trailing clause about a required modifier being missing. That phrasing is legacy and is no longer part of the official text, so do not quote it in an appeal.

CARC 11 | “The diagnosis is inconsistent with the procedure.” Where you see it: a destruction or removal code submitted with a diagnosis from the wrong family.

CARC 18 | “Exact duplicate claim/service.” Where you see it: TC/26 splits billed alongside the global code.

CARC 50 | “These are non-covered services because this is not deemed a ‘medical necessity’ by the payer.” Where you see it: the cosmetic classification denial. The clinical record did not establish a covered condition, or the covered condition never made it onto the claim.

CARC 97 | “The benefit for this service is included in the payment/allowance for another service/procedure that has already been adjudicated.” Where you see it: bundling. Note the “already been adjudicated” clause, because it tells you the other service is already paid and this one is not coming separately.

CARC 119 | “Benefit maximum for this time period or occurrence has been reached.” Where you see it: preventive benefit collisions, covered in the next section.

CARC 167 | “This (these) diagnosis(es) is (are) not covered.” Where you see it: the diagnosis itself is excluded under the plan. This is not the same as CARC 11. 167 says the diagnosis is not covered. 11 says the diagnosis does not go with the procedure. Different problems, different appeals, and they are frequently conflated.

CARC 234 | “This procedure is not paid separately.” Where you see it: alongside 97 on NCCI-bundled pairs.

CARC 236 | “This procedure or procedure/modifier combination is not compatible with another procedure or procedure/modifier combination provided on the same day according to the National Correct Coding Initiative or workers compensation state regulations/fee schedule requirements.” Where you see it: mutually exclusive pairs. Note that the official definition is explicitly sensitive to the modifier combination, which is another reason to check the indicator rather than assume.

The complete current list lives at x12.org/codes/claim-adjustment-reason-codes. It is free, it is authoritative, and it is worth checking against rather than trusting a definition you have carried in your head for a few years. I have had to correct my own more than once.

The skin cancer screening trap

This one surprises people, so it gets its own section.

The U.S. Preventive Services Task Force gives routine skin cancer screening a grade of I, meaning current evidence is insufficient to assess the balance of benefits and harms. That grade was issued April 18, 2023, and it affirms the same conclusion USPSTF reached in 2016.

The billing consequence follows from the grade. Medicare’s authority to cover additional preventive services requires an A or B recommendation. So does the ACA’s requirement that plans cover a service without cost-sharing. With a grade of I, neither applies. Skin cancer screening is not a covered preventive benefit.

A visit billed with preventive codes for a skin cancer screen will typically come back as CARC 119 or CARC 96.

The fix is matching the code to the clinical content rather than to the reason the patient gave when scheduling. If a suspicious lesion was identified and evaluated, and medical decision-making occurred, that is a problem-focused E/M supported by a specific diagnosis. That is not a workaround. It is what actually happened at the visit.

Documentation practices that prevent the denial

Dermatology billing problems are documentation problems that have aged. These five address them upstream.

  1. Build a modifier 25 template that forces separation. The E/M note and the procedure note should be distinct sections with distinct chief complaints. If both issues are dermatologic, the E/M section still needs history, exam, and decision-making for the non-procedure condition, written with enough specificity to stand on its own.

  2. Document medical justification for every lesion treated. Each lesion needs site, size, clinical characteristics, method, and the diagnosis supported by the findings. “Lesion destroyed” with no further detail is unappealable when it denies, and you will not be able to reconstruct it later.

  3. Complete Mohs staging before the patient leaves the room. Map, dimensions, margin interpretation, and the decision to proceed or close, for every stage, contemporaneously.

  4. Verify diagnosis codes against payer coverage lists before submission, not after denial. Maintain a reference of which diagnoses support coverage for your highest-volume procedures, by payer. A medically necessary removal coded with a cosmetic diagnosis denies every time regardless of what the note says. This is a front-end fix and there is no appeal that substitutes for it.

  5. Audit TC/26 splits quarterly. See the pathology section above.

Frequently asked questions

When is modifier 25 justified?

When the E/M is significant and separately identifiable from the work inherent to the procedure. It needs a separate chief complaint or condition, independent history, exam, and decision-making, and documentation that reads as a distinct service. A restatement of the pre-procedure assessment does not qualify, because that assessment is part of every procedure.

What is the difference between modifier 59 and the X modifiers?

Modifier 59 means distinct procedural service and is the general-purpose NCCI bypass. The X modifiers are more specific: XE for a separate encounter, XP for a separate practitioner, XS for a separate structure, XU for an unusual non-overlapping service. Per NCCI Policy Manual Chapter 1, use 59 only when no other modifier more appropriately describes the relationship. XS is the one dermatology uses most.

How do I document medical necessity for actinic keratosis destruction? You need the confirmed clinical or pathologic diagnosis, the location, size, and clinical characteristics of each lesion, the destruction method, and the clinical rationale. L57.0 is the diagnosis for actinic keratosis. Payers routinely request records when multiple lesions are destroyed on one date, so document each lesion individually rather than as a group. Coverage criteria for premalignant lesion destruction are set by your MAC, so check your own jurisdiction’s LCD and its companion billing and coding article.

Can I bill a biopsy and an excision on the same day?

Different lesions, yes, with the appropriate modifier and documentation showing they were different lesions. Same lesion, no. The biopsy is included in the removal per NCCI Policy Manual Chapter 3. If the excision happens at a later encounter based on the pathology result, both are billable, and remember that the later excision is often a malignant excision coding to 11600-11646.

How do TC and 26 work for in-office pathology?

The entity processing the specimen bills TC. The interpreting pathologist bills 26. An entity doing both bills the global code with no modifier. Billing global plus a component modifier for the same date generates a CARC 18 duplicate. This does not apply to Mohs, where the interpretation is already inside the Mohs code and separate pathology billing signals that Mohs was not performed.

When does a cosmetic procedure become medically necessary?

When it addresses documented functional impairment, recurrent infection, pain, bleeding, or clinical risk rather than appearance alone. The record has to state the functional problem explicitly and explain why conservative management is not sufficient. Diagnosis selection carries the whole thing: Z41.1 will deny regardless of what the procedure note says.

Can a skin cancer screening visit be billed as preventive in 2026?

No. USPSTF grades routine skin cancer screening as I (insufficient evidence), so Medicare does not cover it as a preventive benefit and ACA-compliant plans are not required to cover it without cost-sharing. If a suspicious lesion was evaluated with medical decision-making, bill a problem-focused E/M with a specific diagnosis. Code what happened, not what was scheduled.

Which CARC codes show up most in dermatology?

In my experience the recurring set is 4 (modifier problems), 97 and 234 (bundling), 50 (medical necessity and cosmetic classification), 11 and 167 (diagnosis problems, and they are different from each other), 119 and 96 (preventive and non-covered), 18 (pathology duplicates), and 236 (mutually exclusive pairs). I would treat that as a starting list for your own denial review rather than a ranking, because the mix varies more by payer than most benchmarking suggests.

How we work on this at ROI

Dermatology denials are patterned. The same modifier errors, the same bundling pairs, and the same cosmetic documentation gaps show up across practices of very different sizes, which is what makes them worth systematizing.

If you want to see where your own denial mix sits before deciding whether any of that is useful, the revenue health assessment is free and will tell you where the recoverable dollars are concentrated.

“The cosmetic line, the modifier rules, and the bundling edits are all knowable in advance. That is the good news and the uncomfortable news at the same time. A dermatology denial is almost always something that could have been prevented at the note or at the claim, which means it is almost always something you can fix.”

Mindy Corbett, CSPO, CPC, CPB, CPPM, Founder, Revenue Optimization & Intelligence

Something not working the way you expect?

If you are stuck on a specific denial, or something in this guide does not match what you are seeing from your payer, tell me. I would rather fix the guide than have the next person hit the same wall.

Sources

  1. Centers for Medicare & Medicaid Services. National Correct Coding Initiative Edits. https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits
  2. Centers for Medicare & Medicaid Services. 2026 NCCI Medicare Policy Manual, Chapter 1 (modifiers). https://www.cms.gov/files/document/01-chapter1-ncci-medicare-policy-manual-2026-final.pdf
  3. Centers for Medicare & Medicaid Services. 2026 NCCI Medicare Policy Manual, Chapter 3 (integumentary system). https://www.cms.gov/files/document/03-chapter3-ncci-medicare-policy-manual-2026-final.pdf
  4. Centers for Medicare & Medicaid Services. MLN1783722, Proper Use of Modifiers 59, XE, XP, XS, and XU. https://www.cms.gov/files/document/mln1783722-proper-use-modifiers-59-xe-xp-xs-xu.pdf
  5. Centers for Medicare & Medicaid Services. Billing and Coding: Mohs Micrographic Surgery (A56515). https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56515
  6. CGS Administrators. Local Coverage Determination: Cosmetic and Reconstructive Surgery (L39506), Kentucky and Ohio. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39506
  7. Novitas Solutions. Local Coverage Determination: Removal of Benign Skin Lesions (L34938). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34938
  8. Centers for Medicare & Medicaid Services. Recovery Audit topic 0121: Destruction of Premalignant Lesions, Excessive Units. https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/medicare-fee-service-recovery-audit-program/approved-rac-topics/0121-destruction-premalignant-lesions-excessive-units
  9. U.S. Preventive Services Task Force. Skin Cancer: Screening (Grade I, April 18, 2023). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening
  10. American Medical Association. CPT 2026 Professional Edition. AMA Press, 2025.
  11. American Academy of Dermatology. Coding Resource Center. https://www.aad.org/member/practice/coding
  12. X12.org. Claim Adjustment Reason Codes. https://x12.org/codes/claim-adjustment-reason-codes